Soligenix appoints new VP of biopharmaceutical development

Solgenix appoints VP of Biopharmaceutical Development
Solgenix appoints VP of Biopharmaceutical Development
Soligenix, Inc., a biopharmaceutical company developing products in the areas of inflammation, oncology and biodefense, named Rasappa Arumugham vice president of biopharmaceutical development on Tuesday. 

With 25 years of experience in the biopharmaceutical field, Arumuguam previously served as the head of microbial vaccines analytics at Merck's manufacturing division. He holds a Ph.D. and Master's degree in biochemistry and a Bachelor's degree in chemistry from the University of Madras, India. 

"We are delighted to welcome Dr. Arumugham to our team, as we leverage his extensive pharmaceutical drug development expertise in leading our vaccines/biodefense and biotherapeutic programs,"  Christopher J. Schaber, the president and CEO of Soligenix, said. "As we continue to execute our growth strategy, we are clearly building momentum and the talent we are attracting is an absolute reflection of our solid progress to date."

Soligenix is working on developing defense measures as part of the U.S. government's Biomedical Advanced Research and Development Authority Strategic Plan of 2011-2016, which includes a strategic national stockpile.

Soligenix received a contract from the National Institute of Allergy and Infectious Diseases to pursue experiments regarding treatments and preventions for ricin exposure. In addition, Soligenix is working with Intrexon Corporation to develop a treatment for Melioidosis, an infectious disease that is caused by a bacterium found in soil and water.